Thu, May 15, 8:09 PM (36 days ago)
**vTv Therapeutics Inc. (VTVT) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 (Q1 2024: $1,000,000) - **Operating Expenses:** $6,503,000 (Q1 2024: $6,627,000) - **Research & Development:** $2,830,000 (Q1 2024: $2,649,000) - **General & Administrative:** $3,673,000 (Q1 2024: $3,978,000) - **Operating Loss:** $6,503,000 (Q1 2024: $5,627,000) - **Net Loss:** $5,092,000 (Q1 2024: $4,865,000) - **Cash & Cash Equivalents:** $31,059,000 (Q1 2024: $52,255,000) - **Accumulated Deficit:** $304,810,000 (Q1 2024: $299,718,000) **Profit Margins:** - **Operating Margin:** -100% (Q1 2024: -562.7%) - **Net Margin:** -100% (Q1 2024: -486.5%) **Cash Flow:** - **Net Cash Used in Operating Activities:** $5,687,000 (Q1 2024: $7,335,000) - **No Cash Flows from Investing Activities** - **No Cash Flows from Financing Activities** (Q1 2024: $50,144,000) **Earnings Changes:** - **Net Loss per Share:** $0.77 (Q1 2024: $1.17) **Trends & Uncertainties:** - **Revenue:** No revenue generated in Q1 2025; revenue in Q1 2024 was due to a milestone payment. - **Expenses:** Slight increase in R&D expenses; decrease in G&A expenses. - **Cash Position:** Significant decrease in cash position due to no financing activities in Q1 2025. - **Going Concern:** Substantial doubt about the company's ability to continue as a going concern due to negative cash flows and the need for additional financing. **Future Operations Impact:** - **Funding:** Company is evaluating financing strategies to increase cash runway, including equity investments and licensing/monetization of other programs. - **Clinical Trials:** Company continues to work on the design of international registrational studies for cadisegliatin in type 1 diabetes, expected to start in 2027. - **Partnerships:** Company is working with G42 Investments to initiate a Phase 2 trial in the Middle East region for type 2 diabetes, expected to begin in 2025. **Key Metrics:** - **Cash Burn Rate:** $5,687,000 per quarter (Q1 2025) - **Cash Runway:** Approximately 5.5 quarters (based on Q1 2025 cash burn rate and ending cash balance) - **Operating Loss Growth:** 15.9% increase in operating loss compared to Q1 2024.